Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 8, 2019

Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008)

Joel M. Trugman, David W. Dodick, Jessica Ailani, Kaifeng Lu, Hassan Lakkis, Michelle Finnegan, Armin Szegedi, Richard B. Lipton
First published April 16, 2019,
Joel M. Trugman
1Allergan plc Madison NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Dodick
2Mayo Clinic Scottsdale AZ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Ailani
3MedStar Georgetown University Hospital Washington DC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaifeng Lu
1Allergan plc Madison NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hassan Lakkis
1Allergan plc Madison NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Finnegan
1Allergan plc Madison NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armin Szegedi
1Allergan plc Madison NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard B. Lipton
4Albert Einstein College of Medicine Bronx NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: Results From a Single-Attack Phase 3 Study, ACHIEVE II (S38.008)
Joel M. Trugman, David W. Dodick, Jessica Ailani, Kaifeng Lu, Hassan Lakkis, Michelle Finnegan, Armin Szegedi, Richard B. Lipton
Neurology Apr 2019, 92 (15 Supplement) S38.008;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the efficacy, safety, and tolerability of ubrogepant for acute treatment of migraine.

Background: Ubrogepant, a novel, orally active, calcitonin gene–related peptide receptor antagonist, is in development for the acute treatment of migraine.

Design/Methods: Multicenter, double-blind, phase 3 study (NCT02867709). Adults with a history of migraine were randomized (1:1:1) to placebo or ubrogepant (25mg or 50mg). Patients had 60 days to treat a single migraine attack (moderate/severe pain intensity). Co-primary efficacy endpoints (2h post initial dose) were headache pain freedom and absence of the most bothersome migraine-associated symptom (MBS) identified before treatment. Secondary efficacy endpoints included pain relief, sustained pain relief, sustained pain freedom, and absence of individual migraine-associated symptoms.

Results: 1686 patients were randomized (n=1465, safety population; n=1355, mITT population). Mean age: 41 years; majority white (81%) and female (89%). Compared with placebo, significantly greater proportions of ubrogepant-treated patients achieved 2-hour pain freedom (both ubrogepant doses [placebo: 14.3%; 25mg: 20.7%, adjusted P=0.0285; 50mg: 21.8%, adjusted P=0.0129]) and 2-hour absence of MBS for 50mg (placebo: 27.4%; 50mg: 38.9%, adjusted P=0.0129). All secondary efficacy endpoints (except absence of nausea at 2h) met statistical significance versus placebo for the 50mg dose. Pain relief rates (2h) were higher for ubrogepant 50mg than placebo (62.7% vs 48.2%, adjusted P=0.0129). Secondary efficacy outcomes were not significant for the 25mg dose. Ubrogepant’s and placebo’s AE profiles were similar.

Conclusions: In ACHIEVE II, both co-primary efficacy endpoints were met, with clinically meaningful effects for the 50mg ubrogepant dose. Ubrogepant 25mg was significantly superior to placebo for 2h pain freedom but not the MBS co-primary endpoint. Additionally, 62.7% of ubrogepant-treated patients who received 50mg achieved pain relief at 2h. Ubrogepant was well tolerated. These results confirm those previously reported (ACHIEVE I), together supporting the efficacy, tolerability, and safety of ubrogepant for acute treatment of migraine.

Disclosure: Dr. Trugman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Trugman holds stock and/or stock options in Allergan plc. which sponsored research in which Dr. Trugman was involved as an investigator. Dr. Trugman holds stock and/or stock options in Allergan plc. Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Dodick reports personal fees from Acorda, Amgen, Alder, Allergan, Autonomic Technologies, Biohaven, Colucid, Eli Lilly, eNeura, Foresight Capital, Neurolief, Zosano, WL Gore, Vedanta Associates, Promius Pharma, Magellan Healthcare, CC West Ford Group, Nocira, Novartis, NuPathe, Supernus, Electrocore, Tonix, Teva, Alcobra, Insys, Ipsen, Charleston Laboratories, Biocentric, Theranica, Xenon. ZP Opco. Travel expense reimbursement and speaking fee from Sun Pharma. Anticipated income from consulting within next 3 weeks not previously reported: Impel pharmaceuticals (currently under review by Mayo Clinic Medical Industry Relations Committee). Compensation for activities related to data safety monitoring committee from Axsome. Speaking fees, or fees related to CME content development: Healthlogix, Medicom Worldwide, Medlogix Communications, MedNet, Miller Medical Communications, PeerView Operation Services America, Web MD/Medscape, American Academy of Neurology, American Headache Society, PeerView Institute for Medical Education, Chameleon Communications, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket Medical Education, Global Scientific Communications, UpToDate, Meeting LogiX. Consulting use agreement through employer: NeuroAssessment Systems, Myndshft. Dr. Dodick has received compensation for serving on the Board of Directors of Board of Directors position: King-Devick Technologies, Ontologics. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, which sponsored research in which Dr. Dodick was involved as an investigator. Dr. Dodick holds stock and/or stock options in Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, and Epien. Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Biohavin, Eli Lilly and Company, Electrocore, Promius, Teva, Impel, Satsuma, Aptus, Alpha Sites and Miller Medical Communications. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports (section editor). Dr. Ailani has received research support from ARMR/American Migraine Foundation and Biohaven. Dr. Lu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Lu holds stock and/or stock options in Allergan plc. which sponsored research in which Dr. Lu was involved as an investigator. Dr. Lu holds stock and/or stock options in Allergan plc.. Dr. Likis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Likis holds stock and/or stock options in Allergan plc. which sponsored research in which Dr. Likis was involved as an investigator. Dr. Likis holds stock and/or stock options in Allergan plc.. Dr. Finnegan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan plc. Dr. Finnegan holds stock and/or stock options in Allergan plc. which sponsored research in which Dr. Finnegan was involved as an investigator. Dr. Finnegan holds stock and/or stock options in Allergan plc. Dr. Szegedi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as a full-time employee of Allergan plc and stockholder of Allergan and Merck. Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder Biopharmaceuticals, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir Pharmaceuticals, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton holds stock and/or stock options in Biohaven.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise